# Boston Scientific

**Source:** https://geo.sig.ai/brands/boston-scientific  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** bostonscientific.com  
**Last Updated:** 2026-04-14

## Summary

Marlborough MA cardiac devices leader (NYSE: BSX) $16.7B FY2024 revenue (+18%); Farapulse PFA ablation fastest-growing EP device, WATCHMAN FLX 70%+ LAAC share, competing with Abbott and Medtronic.

## Company Overview

Boston Scientific Corporation is a Marlborough, Massachusetts-based global medical device company — publicly traded on the New York Stock Exchange (NYSE: BSX) as an S&P 500 Health Care component — developing and commercializing medical devices for minimally invasive diagnosis and treatment of cardiovascular disease, cardiac rhythm management, electrophysiology, urology, endoscopy, and neuromodulation through approximately 48,000 employees in 130 countries. In fiscal year 2024, Boston Scientific reported revenues of $16.7 billion (+18% year-over-year) — driven by the Farapulse pulsed field ablation (PFA) system for atrial fibrillation treatment, WATCHMAN FLX left atrial appendage closure (LAAC) device, and Rhythmia Ultra high-density cardiac mapping — making Boston Scientific the fastest-growing large-cap medical device company and one of the strongest organic growth stories in healthcare. CEO Mike Mahoney has executed acquisitions and organic R&D investment to build a diverse cardiovascular and electrophysiology portfolio: the 2023 acquisition of Apollo Endosurgery ($615 million, flexible endoscopic stapling for minimally invasive procedures) and the 2022 acquisition of Lumenis (surgical laser systems) expanded Boston Scientific beyond the cardiac core. Boston Scientific's strongest 2024 growth driver — Farapulse (pulsed field ablation) — achieved rapid adoption as a new standard-of-care in atrial fibrillation ablation by delivering shorter procedure times (2-hour PFA versus 4-hour radiofrequency ablation) and improved safety profile compared to traditional thermal ablation methods.

Boston Scientific's medical device portfolio model creates competitive advantages through the procedure-embedded clinical training and physician adoption dynamics of minimally invasive cardiac devices: an electrophysiologist who trains on Farapulse PFA at Boston Scientific's hands-on simulation lab (BSC's Electrophysiology Learning Centers in Boston, Minneapolis, and Amsterdam) becomes a trained Farapulse operator — building procedural volume on Farapulse catheters, generators, and mapping systems that create quarterly reorder revenue from the BSC distributor relationship. The WATCHMAN FLX LAAC device (implanted in the left atrial appendage to prevent stroke in atrial fibrillation patients who cannot take blood thinners) has generated over 100,000 cumulative implants globally and holds 70%+ market share in the LAAC market against the only competitor (Abbott's Amulet device) — creating dominant installed base and physician training advantage that new LAAC entrants cannot easily displace. Boston Scientific's electrophysiology portfolio depth (Rhythmia Ultra mapping, Farapulse ablation, CARTO integrated workflow with J&J collaboration, and LATITUDE remote monitoring) creates system value for hospital EP labs that select the full Boston Scientific ecosystem over piecemeal competitive device selection.

In 2025, Boston Scientific competes in electrophysiology, cardiac rhythm management, and urology/endoscopy against Abbott Laboratories (NYSE: ABT, Amulet LAAC, CardioMEMS, TactiCath cardiac mapping), Medtronic (NYSE: MDT, pulsed field ablation entry with PulseSelect system, Arctic Front cardiac ablation), and Johnson & Johnson's MedTech (NYSE: JNJ, Biosense Webster CARTO mapping, Thermocool ablation catheter) for electrophysiology lab capital equipment purchases, atrial fibrillation ablation procedure volume, and LAAC device market leadership. Medtronic's PulseSelect PFA system launch in 2024 created direct competition for Farapulse in the high-growth pulsed field ablation market — requiring BSC to defend early market share through physician training scale and clinical evidence superiority. The urology segment growth (SpaceOAR hydrogel for prostate radiation protection, LithoVue single-use ureteroscope) and neuromodulation segment (Precision Montage MRI-conditional spinal cord stimulation) provide revenue diversification that balances cardiac cycle risk. The 2025 strategy focuses on Farapulse pulsed field ablation market development (global EP lab adoption, physician training at scale), WATCHMAN FLX LAAC expansion into type 2 diabetes/obesity patient risk stratification, and emerging markets cardiovascular infrastructure investment.

## Frequently Asked Questions

### What is Boston Scientific?
Boston Scientific is a global leader in medical technology that develops, manufactures, and markets innovative medical devices used in interventional medical specialties. The company serves multiple specialties including interventional cardiology, electrophysiology, endoscopy, neuromodulation, peripheral interventions, and various surgical applications. With approximately 63,000 employees worldwide, Boston Scientific's mission is to transform lives through innovative medical solutions that improve patient health globally.

### When was Boston Scientific founded?
Boston Scientific was founded on June 29, 1979, by Pete Nicholas and John Abele in Watertown, Massachusetts. The company started as a holding company for Medi-Tech, Inc., with fewer than 50 employees, financed with a $500,000 loan and $300,000 in partners' capital. The founders pioneered the use of steerable catheters for less-invasive medical procedures, establishing the foundation for the company's decades of innovation.

### Where is Boston Scientific headquartered?
Boston Scientific is headquartered in the United States, with major operations in Marlborough, Massachusetts, and significant global presence. The company operates manufacturing facilities, research centers, and commercial offices worldwide to serve healthcare providers and patients across international markets. Approximately 58% of the company's workforce is located outside the United States.

### Who are Boston Scientific's customers?
Boston Scientific's primary customers are healthcare providers including hospitals, surgery centers, physicians' offices, and clinics worldwide. The company serves interventional cardiologists, electrophysiologists, endoscopists, peripheral interventionalists, pain management specialists, urologists, and other medical professionals who use Boston Scientific's devices to treat patients. Ultimately, the company's products benefit millions of patients globally who require less-invasive medical treatments.

### What is Boston Scientific's revenue and financial performance?
In fiscal year 2024, Boston Scientific achieved record revenue of $16.75 billion, representing 17.6% growth year-over-year. The company reported net income of $1.85 billion. Revenue is divided between the Cardiovascular segment ($10.76 billion, 64% of total) and MedSurg segment ($5.99 billion, 36% of total). Geographically, the United States generates 61% of revenue while international markets contribute 39%. The company has a market capitalization of approximately $146 billion as of 2025.

### How many employees does Boston Scientific have?
As of December 2024, Boston Scientific employs approximately 63,000 people globally, representing 9% growth from December 2021. The company maintains a diverse workforce with approximately 58% of employees located outside the United States. Boston Scientific has achieved over 99% pay equity as of 2024 and maintains a strong workplace culture with 91% of employees expressing pride in working for the company.

### What makes Boston Scientific different from competitors?
Boston Scientific differentiates itself through its commitment to meaningful innovation, comprehensive product portfolio across multiple interventional specialties, and track record of bringing first-to-market technologies to patients. The company pioneered less-invasive procedures with steerable catheters and continues to lead with breakthrough devices like the AGENT drug-coated balloon (first FDA-approved coronary DCB in the U.S.) and the modular cardiac rhythm management system. The company's diversified portfolio across cardiovascular and MedSurg segments provides stability while its innovation pipeline drives growth.

### Who are Boston Scientific's main competitors?
Boston Scientific competes with multiple medical device manufacturers depending on the product category. Key competitors include Medtronic (cardiac rhythm management, neuromodulation), Abbott Laboratories (cardiovascular devices, structural heart), Johnson & Johnson/Biosense Webster (electrophysiology), Edwards Lifesciences (structural heart), and Stryker (endoscopy, neurovascular). The competitive landscape varies by geography and medical specialty, with Boston Scientific holding leadership positions in several device categories.

### What recent acquisitions has Boston Scientific made?
In 2024, Boston Scientific completed two major acquisitions: Axonics, Inc. for $3.7 billion in November (adding sacral neuromodulation systems for urology applications) and Silk Road Medical for $1.28 billion in September (adding TCAR technology for stroke prevention). Both acquisitions underwent extended FTC regulatory review before closing and significantly expand Boston Scientific's capabilities in high-growth medical device markets.

### Is Boston Scientific hiring?
Yes, Boston Scientific actively recruits talent across its global operations in engineering, research and development, clinical affairs, sales and marketing, manufacturing, quality and regulatory, and corporate functions. The company has grown from approximately 48,000 employees in 2023 to 63,000 in 2024, reflecting strong business expansion. Interested candidates can explore opportunities on the company's careers website.

### What is Boston Scientific's outlook for 2025?
Boston Scientific anticipates strong continued growth in 2025, with organic revenue growth projected at 12-14% for the full year despite a $200 million tariff impact. The company plans to launch the EMPOWER leadless pacemaker in the second half of 2025 and expects FDA approval for its modular cardiac rhythm management system. CEO Mike Mahoney has expressed being 'very bullish' on 2025 prospects, driven by the company's innovation pipeline and market expansion opportunities.

### What are Boston Scientific's core values?
Boston Scientific's core values include Caring (acting with integrity and compassion), Meaningful Innovation (fostering creativity to transform ideas into breakthrough solutions), High Performance (striving for excellence to benefit patients and shareholders), Global Collaboration (working across borders to extend reach), Diversity (embracing unique talents and experiences), and Winning Spirit (adapting with speed and agility to improve patient care). These values guide the company's culture and decision-making across its 63,000-person global workforce.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*